CMPS

COMPASS Pathways plc (NASDAQ:CMPS) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in London, United Kingdom. The company went public in September 2020 and focuses exclusively on developing psilocybin-based therapies for mental health conditions. COMPASS represents one of the pioneering companies in the emerging field of psychedelic medicine, seeking to bring scientifically rigorous approaches to substances that were previously relegated to recreational or underground therapeutic use. The company's primary asset is COMP360, a proprietary psilocybin therapy currently in Phase III clinical trials for treatment-resistant depression.